Results also showed 27.7 percent of patients in the ADT plus
docetaxel arm had a decline in prostate specific antigen (PSA) to less than 0.2 ng / mL at 12 months compared with 16.8 percent for those taking ADT alone.
Not exact matches
Disease - free survival was similar in the 9 - week and 12 - month
arms among those patients who received 100 mg / m2
docetaxel.
«In all the subgroups we tested the longer
arm tended to be better than the shorter one, but we did detect an interaction between
docetaxel dose and disease - free survival,» Joensuu said.